You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Application of CDX-MDM in Pre-Clinical Model of Murine Pulmonary Emphysema

    SBC: Covenant Therapeutics LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): The objective of this proposal is to exploit a newly discovered anti-inflammatory function involving the aminopeptidase activity of the leukotriene A4 hydrolase for the treatment of pulmonary emphysema. The leukotrieneA4 hydrolase is a dual-functioning enzyme with dichotomously opposing functions. As an epoxide hydrolase, it catalyzes the conversion of leukotri ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Remote focusing through spatial light modulation for multifocal multiphoton micro

    SBC: BOULDER NONLINEAR SYSTEMS, INC.            Topic: NIMH

    DESCRIPTION (provided by applicant): Nonlinear optical microscopy techniques (such as two-photon florescence) are being used to acquire volumetric (i.e. three dimensional) images that probe several hundred microns into scattering tissue. These techniques are being combined with fast acquisition schemes to allow imaging of live, moving specimens at high NA. This combination allows for high-resoluti ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Neurorestorative therapy of stroke with HUCBC in T2DM rats

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Body Worn EMG Controlling of Assistive Robotic Arm for Stroke Rehabilitation

    SBC: ADVANCED MEDICAL ELECTRONICS CORP            Topic: NINDS

    DESCRIPTION (provided by applicant): Stroke is the leading cause of adult disability and the third leading cause of death in the United States. Approximately 15 million people in the world, and more than 700,000 people in the United States, experience a stroke each year. Following a hemispheric stroke, motor control of extremities on one side of the body is usually affected. Many patients suffer a ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model

    SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION            Topic: N

    DESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Repurposing Pyrvinium as an Orphan Drug for Familial Adenomatous Polyposis

    SBC: Stemsynergy Therapeutic            Topic: 102

    DESCRIPTION provided by applicant The tumor suppressor Adenomatous Polyposis Coli APC directs degradation of catenin a central signaling protein in the WNT pathway Germline loss of function mutations in APC activate WNT signaling and underlie the inherited colorectal cancer predisposition syndrome Familial Adenomatous Polyposis FAP an orphan disease while somatic mutations lead to spo ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Assay System and Analysis Algorithm in Detecting RNA Editing Events and Linked Splicing Isoforms

    SBC: Celetrix LLC            Topic: NIDA

    Abstract RNA editing is a process in which the genome encoded information is altered in RNA RNA editing is an efficient way to increase RNA complexity thereby fine tuning both gene function and dosage Adenosine to Inosine A to I editing is the most common type of RNA editing known in animals The cellular machinery recognizes inosine as guanosine so A to I editing of codons and splicing sign ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. A cloud-based secure patient information exchange framework for managing treatment accessibility, utilization, quality, and outcomes in behavioral health clinics

    SBC: Waldron International llc            Topic: NIDA

    DESCRIPTION In communities across the United States clinical populations exhibiting mental health and or substance abuse disorders face substantial challenges in accessing and receiving high quality and effective behavioral healthcare services Health Information technology HIT has been identified as an important component of improving access to behavioral healthcare in rural communities yet t ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Optimizing Vaccines by Targeting Dendritic Cells with IFNa and IFNb Inducing Adjuvants

    SBC: PARABON NANOLABS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant There is a critical need for a safe and effective vaccine against HIV Decades of work have been invested in understanding the immune response to infection and different approaches have been taken to develop vaccines that are effective in preventing and treating the disease While effective in animal models none have been as effective in humans The immune ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. High-potency nitro antimicrobials for topical treatment of trichomoniasis

    SBC: DESIGNMEDIX, INC.            Topic: R

    DESCRIPTION provided by applicant Trichomonas vaginalis is the causative agent of the most common non viral sexually transmitted infection with million new cases reported annually in the world and million cases in the U S In addition to infections of the urogenital tract trichomoniasis increases the risk of adverse pregnancy outcomes and HIV transmission and increases the incidence ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government